Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 20/20 | 0.61 |
| ▸ | CRBN | Q96SW2 | 20/20 | 0.61 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22836040 | 1.00 | DDB1 (0.61) | DDB1CRBNIKZF3ALDH1A1CHRM2 | |
| Hydrochloric Acid SCHEMBL26099157 | 0.99 | DDB1 (0.60) | DDB1CRBNIKZF3ALDH1A1CHRM2 | |
| SCHEMBL30318017 | 0.96 | CRBN (0.56) | DDB1CRBNIKZF3 | |
| SCHEMBL24608008 | 0.96 | CRBN (0.56) | DDB1CRBNIKZF3 | |
| SCHEMBL25336425 | 0.92 | CRBN (0.54) | DDB1CRBNIKZF3 | |
| SCHEMBL24481059 | 0.92 | DDB1 (0.56) | DDB1CRBNIKZF3 | |
| SCHEMBL30602904 | 0.92 | DDB1 (0.56) | DDB1CRBNIKZF3 | |
| Trifluoroacetic Acid SCHEMBL26103123 | 0.92 | CRBN (0.52) | DDB1CRBN | |
| SCHEMBL23536394 | 0.91 | DDB1 (0.55) | DDB1CRBNIKZF3 | |
| SCHEMBL31726939 | 0.91 | DDB1 (0.55) | DDB1CRBNIKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062426-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4673449-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | Differentiated Therapeutics Inc (US) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024182555-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062426-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | CCNA1, CCNE1, CCNA2 | DDB1 308/4885CRBN 429/4885IKZF3 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.